PaizaBio Introduces Aseptic Services for China Market
Contract manufacturer PiazaBio announces services for Western Pharma companies seeking to enter the China market.
PaizaBio, a contract manufacturer and marketing agent based in Albuquerque, NM, USA, has announced sterile injectable services for Western pharmaceutical companies seeking entry into China’s market.
PaizaBio reports in a company announcement that it has implemented processes and services to ensure quality, competitiveness, and transparency in China, including a training program for a qualified aseptic workforce; a digital and video production monitoring system; and lyophilization services.
The company’s manufacturing presence in China includes a 40,000-square-meter compound, encompassing a 25,000-square-meter production facility and 10,000-square-meter warehouse. Production equipment includes nine automated filling lines for vials, cartridges and syringes; 10 capping lines; a packaging facility with automated and manual options; four formulation tanks with a capacity of 3,000 liters; and laboratory facilities for testing, validation, analysis, and development. Additionally, the company offers clients expertise in Chinese regulatory compliance.
Soource: PaizaBio
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
